Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Medifast (MED) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Medifast (MED) over the last 16 years, with Q4 2025 value amounting to $89.3 million.

  • Medifast's Cash & Equivalents fell 178.71% to $89.3 million in Q4 2025 from the same period last year, while for Dec 2025 it was $89.3 million, marking a year-over-year decrease of 178.71%. This contributed to the annual value of $89.3 million for FY2025, which is 178.71% down from last year.
  • Per Medifast's latest filing, its Cash & Equivalents stood at $89.3 million for Q4 2025, which was down 178.71% from $99.5 million recorded in Q3 2025.
  • Over the past 5 years, Medifast's Cash & Equivalents peaked at $206.0 million during Q1 2021, and registered a low of $61.1 million during Q2 2022.
  • Its 5-year average for Cash & Equivalents is $113.3 million, with a median of $102.9 million in 2021.
  • As far as peak fluctuations go, Medifast's Cash & Equivalents plummeted by 6819.11% in 2022, and later soared by 14137.45% in 2023.
  • Over the past 5 years, Medifast's Cash & Equivalents (Quarter) stood at $104.2 million in 2021, then dropped by 15.83% to $87.7 million in 2022, then grew by 7.7% to $94.4 million in 2023, then decreased by 3.72% to $90.9 million in 2024, then dropped by 1.79% to $89.3 million in 2025.
  • Its Cash & Equivalents was $89.3 million in Q4 2025, compared to $99.5 million in Q3 2025 and $101.7 million in Q2 2025.